Drugs / AK150
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07566247 | Apr 2026 → Feb 2029 expected | cancer | Akeso | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-10 | Akeso | Regulatory 全球唯一在研！康方生物首创三抗新药 AK150（ILT2/ILT4/CSF1R）进入临床，三维调控突破免疫治疗难题 akesobio.com ↗
近日，康方生物（9926.HK）全球首创的三特异性抗体新药AK150（ILT2/ILT4/CSF1R三抗）获得国家药品监督管理局药品审评中心临床试验默示许可批准，开展用于治疗晚期恶性实体瘤的临床试验. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-10 | Akeso | 全球唯一在研！康方生物首创三抗新药 AK150（ILT2/ILT4/CSF1R）进入临床，三维调控突破免疫治疗难题 akesobio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07566247 ↗ |
| Route | Intravenous | “IV infusion, administered on Day 1 of each cycle, Q2W,continuous treatment” NCT07566247 ↗ |